menu
Contact
our partners

JLABS @ NYC
101 6th Ave,
New York, NY 10013

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

Wuxi.PNG
biomea.PNG
insilico.png
Charles-River.png

© 2019 A2A Pharma. All rights reserved

ADVISORY BOARD

Screen Shot 2019-09-21 at 1.51.26 PM.png
  • Hematologist, oncologist and author of multiple books on cancer . Trained at Stanford, Oxford and Harvard University.

  • Best known for his books,The Emperor of All Maladies: A Biography of Cancer, which earned him the 2011 Pulitzer Prize, and The Gene: An Intimate History which won international awards and was recognized byThe Washington Post and The New York Times as one of the most influential books of 2016.  

  • Professor of medicine at Columbia University

  • Staff cancer physician at Columbia University’s Medical Center

  • Contributing writer for the New Yorker, The New York Times Magazine

  • Received numerous awards for his scientific work and has published his original research and opinions in journals such as Nature, Cell and the New England Journal of Medicine

Siddhartha Mukherjee, MD, Ph.D 

themedicinemaker.com-3354322557624982.pn
  • A biopharma thought leader with over 25 years of industry experience. Dr. Jenkins has extensive recent experience in building and financing biotech companies pursuing cures for the most challenging rare diseases to address important medical issues globally. 

  • Committee member of the Science Board to the U.S. Food & Drug Administration

  • Board member at Faster Cures a center of The Milken Institute and Chair of The Court The London School of Hygiene and Tropical Medicine.

Annalisa Jenkins, M.B.B.S., F.R.C.P.

  • Professor and Chair of the Department of Tumor Biology since 2010.

  • Distinguished Scholar the Moffitt Cancer Center in Tampa, Florida

  • Holds a PhD in Biochemistry from the Indian Institute of Science, Bangalore and a Postdoctoral Fellowship in Molecular Biology from Duke University Medical Center.

  • Started his independent laboratory at Columbia University in 1992 and his studies focus on regulatory pathways that promote tumor growth, angiogenesis, metastasis and how they can be targeted for drug discovery.

Srikumar Chellappan, Ph.D.